Home Covid News and Updates NTAGI will meet to discuss Gennova Pharmaceuticals’ indigenous mRNA vaccine findings

NTAGI will meet to discuss Gennova Pharmaceuticals’ indigenous mRNA vaccine findings

by Pragati Singh

The Covid working group of the National Technical Advisory Group on Immunisation (NTAGI) is set to meet shortly to discuss India’s first mRNA vaccine against COVID and Biological E’s Corbevax Booster dosage for Covishield and Covaxin recipients, according to sources on Monday. The Drugs Controller General of India (DCGI) recently authorised Gennova Biopharmaceuticals’ 2 dose mRNA vaccine for COVID for restricted use in emergency conditions for those over the age of 18. This vaccine is now stable for storage at temperatures ranging from 2 to 8 degrees Celsius for the first time.

Earlier, the Subject Expert Committee of India’s drug regulator decided that Gennova Biopharmaceuticals’ evidence was sufficient in a meeting conducted on Friday, according to people present at the meeting.

Gennova Biopharmaceuticals submitted the data in April, followed by further information in May.

Dr Sanjay Singh, Chief Executive Officer and Whole-time Director, Gennova Biopharmaceuticals Ltd, stated earlier this month in an exclusive interview with ANI that the business is ready to put out India’s first mRNA vaccine within 72 hours after receiving government approval.

Ntagi’s Permission

“We have the vaccination ready; ideally, as soon as the NTAGI gives us clearance and the government gives us approval, we will be able to roll out within 72 hours,” he added.

Gennova Biopharmaceuticals Ltd’s mRNA vaccine will be marketed under the trade name GEMCOVAC-19.

Depending on demand, the firm has the potential to generate 200-300 million doses.

“At the moment, we can create 200-300 million doses depending on demand, but this can be expanded up since that is the advantage of this technology. Large manufacturing units are not required “Dr. Singh said.

Dr. Singh stated that the vaccine’s cost has not yet been determined, but that the firm is in discussions with the government.

Also Read: Adults with blood cancer react to booster dose of COVID-19 vaccine rather than first dosage: Study

“The vaccine’s cost hasn’t been set yet; it’s being discussed with the government, but it needs to be competitive,” he added.

The indigenous revolutionary mRNAvaccine is based on the second wave powered by the Delta variation and can be stored at temperatures ranging from 2 to 8 degrees Celsius, implying that vaccines may be stored at temperatures ranging from 2 to 8 degrees Celsius. Most other vaccinations must be kept at subzero temperatures.

“mRNA vaccinations have not reached the most vulnerable people due to logistical constraints. We will attempt, and we will travel to many places such as Latin America, Africa, and Southeast Asia. So that we can not only sell vaccines but also establish joint manufacturing facilities in other locations, “When questioned about future plans and vaccine exports, Dr Singh stated.

Follow Medically Speaking on Twitter Instagram Facebook



You may also like